Special NoticeActiveDARPA-SN-26-91
Resuscitation and Prevention of Ischemia-Induced Dysfunction (RAPIID) - TA4
DEPT OF DEFENSE / DEFENSE ADVANCED RESEARCH PROJECTS AGENCY (DARPA) / DEF ADVANCED RESEARCH PROJECTS AGCYKey dates?
- Posted?
- Jun 11, 2026
- Response deadline?
- Jun 29, 2026, 3:00 PM UTC
- Archive date?
- —
- Archive type?
- autocustom
Classification?
- Notice type?
- Special Notice
- Base type?
- Solicitation
- Set-aside?
- —
- Set-aside code?
- —
- PSC?
- AC12
NAICS?
Issuing office?
- Department?
- DEPT OF DEFENSE
- Sub-tier?
- DEFENSE ADVANCED RESEARCH PROJECTS AGENCY (DARPA)
- Office?
- DEF ADVANCED RESEARCH PROJECTS AGCY
- Office code?
- 097.97AE.HR0011
- Organization type?
- OFFICE
- Office address?
- ARLINGTON, VA, 222032114, USA
Contacts?
- LCDR Robert Murray, Program Manager, DARPA/BTOprimary
Description?
The Defense Advanced Research Projects Agency (DARPA) is seeking support for commercialization of technologies to be developed under the upcoming Resuscitation and Prevention of Ischemia-Induced Dysfunction (RAPIID) program. The purpose of this announcement is to notify the community of the RAPIID commercialization goals, initiate dialogue to address program needs, and share the timetable for full proposal submission. This special notice is released under the current DARPA BTO Office Wide Broad Agency Announcement (BAA) HR001126S0003, titled “Biological Technologies.”
Attachments (1)?
- Download📎 DARPA-SN-26-91.pdfapplication/pdf · 385 KB
Similar open contracts
Metadata?
- Notice ID?
- 61a78b0d91244a65b239a1248a80e7af
- Full path?
- DEPT OF DEFENSE.DEFENSE ADVANCED RESEARCH PROJECTS AGENCY (DARPA).DEF ADVANCED RESEARCH PROJECTS AGCY
- Office code?
- 097.97AE.HR0011
- Ingested?
- Jun 12, 2026
- Updated?
- Jul 11, 2026